RIA
HZNP

Regal Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Regal Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,871
Closed -$215K – 330
2020
Q2 		$215K Buy
+3,871
New +$166K 0.04% 298

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Regal Investment Advisors's HZNP Position: Q3 2020 in Review

Regal Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2020, closing a stake of 3,871 shares — an estimated $215K sold.

Regal Investment Advisors first reported a position in HZNP in Q2 2020 and held it in 1 quarter. The position peaked at $215K in Q2 2020. 433 funds tracked by Wall St. Rank hold HZNP as of Q3 2020.

  • Regal Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2020 after selling out during the quarter.
  • Regal Investment Advisors sold 3,871 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2020, an estimated $215K.
  • Regal Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 1 quarter.
  • Regal Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $215K in Q2 2020.
  • 433 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2020.

Based on Regal Investment Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.